Macrophage activation switching:: an asset for the resolution of inflammation

被引:671
作者
Porcheray, F
Viaud, S
Rimaniol, A-C
Léone, C
Samah, B
Dereuddre-Bosquet, N
Dormont, D
Gras, G
机构
[1] CEA, DSV, DRM, Lab Neuro Immuno Virol,SNV,Soc Pharmacol & Immuno, F-92265 Fontenay Aux Roses, France
[2] Univ Paris Sud, Ctr Rech, Serv Sante Armees, IPSC,Lab Neuroimmunol Virol,Serv Neurovirol,UMR E, Fontenay Aux Roses, France
关键词
activation; inflammation; macrophage; versatility;
D O I
10.1111/j.1365-2249.2005.02934.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Macrophages play a central role in inflammation and host defence against microorganisms, but they also participate actively in the resolution of inflammation after alternative activation. However, it is not known whether the resolution of inflammation requires alternative activation of new resting monocytes/macrophages or if proinflammatory activated macrophages have the capacity to switch their activation towards anti-inflammation. In order to answer this question, we first characterized differential human macrophage activation phenotypes. We found that CD163 and CD206 exhibited mutually exclusive induction patterns after stimulation by a panel of anti-inflammatory molecules, whereas CCL18 showed a third, overlapping, pattern. Hence, alternative activation is not a single process, but provides a variety of different cell populations. The capacity of macrophages to switch from one activation state to another was then assessed by determining the reversibility of CD163 and CD206 expression and of CCL18 and CCL3 production. We found that every activation state was rapidly and fully reversible, suggesting that a given cell may participate sequentially in both the induction and the resolution of inflammation. These findings may provide new insight into the inflammatory process as well as new fields of investigation for immunotherapy in the fields of chronic inflammatory diseases and cancer.
引用
收藏
页码:481 / 489
页数:9
相关论文
共 27 条
[1]   A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells [J].
Adema, GJ ;
Hartgers, F ;
Verstraten, R ;
deVries, E ;
Marland, G ;
Menon, S ;
Foster, J ;
Xu, YM ;
Nooyen, P ;
McClanahan, T ;
Bacon, KB ;
Figdor, CG .
NATURE, 1997, 387 (6634) :713-717
[2]   Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli [J].
Buechler, C ;
Ritter, M ;
Orsó, E ;
Langmann, T ;
Klucken, J ;
Schmitz, G .
JOURNAL OF LEUKOCYTE BIOLOGY, 2000, 67 (01) :97-103
[3]   Immunohistochemical identification of type II alternatively activated dendritic macrophages (RM 3/1(+++), MS-1(+/-), 25F9(-)) in psoriatic dermis [J].
DjemadjiOudjiel, N ;
Goerdt, S ;
Kodelja, V ;
Schmuth, M ;
Orfanos, CE .
ARCHIVES OF DERMATOLOGICAL RESEARCH, 1996, 288 (12) :757-764
[4]  
Erwig LP, 1998, J IMMUNOL, V161, P1983
[5]   Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-β, PGE2, and PAF [J].
Fadok, VA ;
Bratton, DL ;
Konowal, A ;
Freed, PW ;
Westcott, JY ;
Henson, PM .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (04) :890-898
[6]  
GOERDT S, 1993, AM J PATHOL, V142, P1409
[7]   Other functions, other genes: Alternative activation of antigen-presenting cells [J].
Goerdt, S ;
Orfanos, CE .
IMMUNITY, 1999, 10 (02) :137-142
[8]   Alternative activation of macrophages [J].
Gordon, S .
NATURE REVIEWS IMMUNOLOGY, 2003, 3 (01) :23-35
[9]  
Hieshima K, 1997, J IMMUNOL, V159, P1140
[10]  
Högger P, 1998, J IMMUNOL, V161, P1883